🟠 Editas Medicine (#EDIT) recently laid off 65% of its staff after shelving reni-cel, its lead gene-editing candidate for sickle cell disease, due to the lack of a commercial partner. #CRISPR #biotech $VRTX $NTLA $PRME $EDIT @FDA